PCN100 COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71995-7
https://www.valueinhealthjournal.com/article/S1098-3015(11)71995-7/fulltext
Title :
PCN100 COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71995-7&doi=10.1016/S1098-3015(11)71995-7
First page :
A270
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
154